{"filing":{"accession_number":"0000914475-26-000045","cik":"0000914475","ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-25","primary_document":"nbix-20260925.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm"},"events":[{"id":35464,"run_id":32665,"accession_number":"0000914475-26-000045","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the appointment of Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, to succeed Sanjay Keswani, M.D. While the disclosure also includes Dr. Keswani's departure and Dr. Roberts' compensatory arrangements (base salary of $825,000, bonus target of 60%, and equity grants totaling approximately $1.25 million), the principal action is the appointment of a named executive officer to a C-suite role. The appointment is material to investors as it affects the Company's leadership and strategic direction.","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39524,"accession_number":"0000914475-26-000045","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, to succeed Sanjay Keswani, M.D. While the disclosure also includes Dr. Keswani's departure and Dr. Roberts' compensatory arrangements (base salary of $825,000, bonus target of 60%, and equity grants totaling approximately $1.25 million), the principal action is the appointment of a named executive officer to a C-suite role. The appointment is material to investors as it affects the Company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:25:27.881202+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39524,"accession_number":"0000914475-26-000045","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, to succeed Sanjay Keswani, M.D. While the disclosure also includes Dr. Keswani's departure and Dr. Roberts' compensatory arrangements (base salary of $825,000, bonus target of 60%, and equity grants totaling approximately $1.25 million), the principal action is the appointment of a named executive officer to a C-suite role. The appointment is material to investors as it affects the Company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:25:27.881202+00:00","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-09-28"}]}